JP2003507426A - 骨折治療薬 - Google Patents

骨折治療薬

Info

Publication number
JP2003507426A
JP2003507426A JP2001518059A JP2001518059A JP2003507426A JP 2003507426 A JP2003507426 A JP 2003507426A JP 2001518059 A JP2001518059 A JP 2001518059A JP 2001518059 A JP2001518059 A JP 2001518059A JP 2003507426 A JP2003507426 A JP 2003507426A
Authority
JP
Japan
Prior art keywords
bone
drug
bisphosphonate
group
fracture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001518059A
Other languages
English (en)
Japanese (ja)
Inventor
デイビッド ジー リトル
Original Assignee
ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン filed Critical ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン
Publication of JP2003507426A publication Critical patent/JP2003507426A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001518059A 1999-08-19 2000-08-17 骨折治療薬 Pending JP2003507426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2325 1995-04-12
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (1)

Publication Number Publication Date
JP2003507426A true JP2003507426A (ja) 2003-02-25

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001518059A Pending JP2003507426A (ja) 1999-08-19 2000-08-17 骨折治療薬

Country Status (16)

Country Link
EP (1) EP1214079A4 (sk)
JP (1) JP2003507426A (sk)
KR (1) KR20020027562A (sk)
CN (1) CN100345548C (sk)
AU (1) AUPQ232599A0 (sk)
BR (1) BR0013416A (sk)
CA (1) CA2381302A1 (sk)
HK (1) HK1048441B (sk)
HU (1) HUP0202396A3 (sk)
IL (1) IL148166A0 (sk)
NO (1) NO20020784L (sk)
NZ (1) NZ517538A (sk)
PL (1) PL353485A1 (sk)
SK (1) SK2382002A3 (sk)
WO (1) WO2001013922A1 (sk)
ZA (1) ZA200202160B (sk)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505886A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−メチレン−１９−ノル−ビタミンｄ誘導体及びビスホスフォネートの組み合わせを含む医薬組成物及び方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062351A1 (en) * 2001-02-06 2002-08-15 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937A (zh) * 2020-11-18 2022-05-27 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
JPH06211667A (ja) * 1992-11-30 1994-08-02 Ciba Geigy Ag 骨折治癒のための特定メタンビスホスホン酸誘導体を含んで成る医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124792C (en) * 1991-12-17 2000-07-04 Ann D. Geddes Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
JPH06211667A (ja) * 1992-11-30 1994-08-02 Ciba Geigy Ag 骨折治癒のための特定メタンビスホスホン酸誘導体を含んで成る医薬組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505886A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−メチレン−１９−ノル−ビタミンｄ誘導体及びビスホスフォネートの組み合わせを含む医薬組成物及び方法

Also Published As

Publication number Publication date
PL353485A1 (en) 2003-11-17
NZ517538A (en) 2003-07-25
HUP0202396A2 (hu) 2002-11-28
WO2001013922A1 (en) 2001-03-01
CN1370071A (zh) 2002-09-18
IL148166A0 (en) 2002-09-12
NO20020784D0 (no) 2002-02-18
NO20020784L (no) 2002-02-18
CN100345548C (zh) 2007-10-31
BR0013416A (pt) 2002-04-30
HUP0202396A3 (en) 2005-02-28
EP1214079A4 (en) 2004-03-24
ZA200202160B (en) 2003-08-27
CA2381302A1 (en) 2001-03-01
HK1048441A1 (en) 2003-04-04
HK1048441B (zh) 2008-02-22
SK2382002A3 (en) 2002-09-10
AUPQ232599A0 (en) 1999-09-09
EP1214079A1 (en) 2002-06-19
KR20020027562A (ko) 2002-04-13

Similar Documents

Publication Publication Date Title
US7612050B2 (en) Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
AU2002244520B2 (en) A drug for use in bone grafting
WO2002098307A1 (en) A device for the delivery of a drug to a fractured bone
Pampu et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis
AU2002244520A1 (en) A drug for use in bone grafting
AU2002221339A1 (en) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
CN105012995B (zh) 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
Ducharme et al. Delayed union, nonunion, and malunion
Oteo-Álvaro et al. Teriparatide (rh [1–34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening
JP2003507426A (ja) 骨折治療薬
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
Kumabe et al. Triweekly administration of parathyroid hormone (1–34) accelerates bone healing in a rat refractory fracture model
Tarvainen et al. Effect of clodronate on fracture healing in denervated rats
CA2353528C (en) Use of ibandronate for promoting osseointegration of endoprostheses
AU781068B2 (en) Drug for treating fractures
PRITCHETT L-dopa in the treatment of nonunited fractures.
Kakar et al. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals
JPH08310965A (ja) 骨癒合促進剤
RU2320353C1 (ru) Материал для медицинского применения
JP2010526064A (ja) 骨組織の成長の育成および保存のための方法および組成物
Heidari et al. Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model
RU2816808C1 (ru) Способ оптимизации репаративного остеогенеза трубчатых костей животных
RU187285U1 (ru) Металлоконструкция для интрамедуллярного остеосинтеза трубчатых костей
Kaczmarek Effect of pulsed electromagnetic field therapy on bone repair and regeneration in two tibia osteotomy models in sheep
Green et al. Postoperative Care, Day by Day

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110913